Home
    Disclaimer
    3-Hydroxyphenazepam molecular structure

    3-Hydroxyphenazepam Stats & Data

    Hpnz 3-hop 3-oh-p 3ohphenazepam 3-ho-phenazepam 3hophenazepam 3-ho-p 3hop
    NPS DataHub
    MW365.61
    FormulaC15H10BrClN2O2
    CAS70030-11-4
    IUPAC7-bromo-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one
    SMILESBrc1ccc2NC(=O)C(O)N=C(c3ccccc3Cl)c2c1
    InChIKeyKRJKJUWAZOWXNV-UHFFFAOYSA-N
    Benzodiazepines; 2020/3. Benzodiazepine; 2021/3. Benzodiazepine; 2022/3. Benzodiazepine
    Chemical Class Benzodiazepine
    Psychoactive Class Depressant
    Half-Life 5-15 hours (estimates vary)

    Effect Profile

    Curated
    Benzodiazepine 7.6

    Strong anxiolysis and euphoria with moderate cognitive impairment, mild sedation

    Anxiolysis×3
    10
    Sedation / Relaxation×2
    5
    Motor / Cognitive Impairment×1
    7
    Euphoria / Mood Lift×1
    10

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    5-15 hours (estimates vary)
    Addiction Potential
    High. As with other benzodiazepines, repeated or frequent use can rapidly lead to tolerance, physiological dependence, and a potentially dangerous withdrawal syndrome.

    Tolerance Decay

    Full tolerance 3d Half tolerance 14d Baseline ~28d

    Benzodiazepine tolerance typically develops within days of frequent use and decays over weeks after cessation. Figures are approximate, based on class-wide patterns and user reports rather than substance‑specific kinetics.

    Cross-Tolerances

    benzodiazepines
    80% ●●○
    Z-drugs
    60% ●○○

    Harm Reduction

    drugs.wiki

    This compound is a potent benzodiazepine; many users report significant effects at sub‑milligram doses, making volumetric dosing in ethanol or propylene glycol the safest practical method to avoid mismeasurement. TripSit’s benzo harm-reduction guidance specifically recommends liquid measurement for RC benzos active under 10 mg. It has a 3‑hydroxy group; by analogy to lorazepam/temazepam/oxazepam, most 3‑hydroxy benzodiazepines are cleared mainly by glucuronidation rather than CYP oxidation, so major CYP interactions may be fewer—this is a structural inference and not yet well-characterized for this exact drug. Strong additive CNS depression occurs with alcohol, opioids, GHB/GBL, barbiturates, tramadol, gabapentinoids, Z‑drugs, and sedating antihistamines; such combinations drive blackout, aspiration, and respiratory depression risks. Combining benzodiazepines with ketamine and other dissociatives increases ataxia and loss‑of‑consciousness risk; if someone becomes unresponsive, place them in the recovery position and seek help. Next‑day psychomotor and cognitive impairment can persist despite feeling ‘sober’; avoid driving or hazardous tasks until at least the following day. Amnesia and ‘delusions of sobriety’ are common across benzos and are frequently reported with 3‑hydroxyphenazepam; pre‑plan doses, avoid redosing for at least 2 hours after onset, and have a sober sitter to limit harm. Tolerance builds quickly with repeated use, and benzodiazepine withdrawal can be severe or life‑threatening; do not escalate doses to chase effects, and never stop chronic use abruptly—medical supervision is recommended for cessation. Novel/RC benzodiazepines are often found in counterfeit tablets with unpredictable potency; use only lab‑checked products where possible and treat any pressed ‘benzo’ of unknown origin as potentially over‑ or under‑dosed. User reports note easy dissolution in propylene glycol for accurate volumetric dosing. While insufflation has been reported anecdotally, non‑oral routes can increase unpredictability and harm; oral solutions offer more controllable kinetics.

    ← Back to 3-Hydroxyphenazepam